Skip to main content
NVST
NYSE Life Sciences

Envista Crushes Q1 Estimates with 14% Sales Growth, Unveils New $300M Share Repurchase

feedReported by Reuters
Sentiment info
Positive
Importance info
9
Price
$28.92
Mkt Cap
$4.412B
52W Low
$16.32
52W High
$30.42
Market data snapshot near publication time

summarizeSummary

Envista Holdings Corp reported robust first-quarter results, with sales rising 14% year-over-year to $705.50 million, significantly beating analyst estimates of $680.05 million. Adjusted diluted EPS also saw a substantial 50% year-over-year increase to $0.36. Further bolstering investor confidence, the company announced a new $300 million share repurchase program. This follows a previous $166 million stock repurchase program mentioned in the 2025 10-K, signaling a continued commitment to shareholder returns. The strong operational performance, evidenced by segment growth across all major businesses, combined with a material capital allocation initiative (the new buyback represents approximately 6.8% of the company's market cap), provides a significant positive catalyst for the stock. Traders will be watching for sustained growth and the execution of the repurchase program.

At the time of this announcement, NVST was trading at $28.92 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $16.32 to $30.42. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


show_chartPrice Chart

Share this article

Copied!

feed NVST - Latest Insights

NVST
May 06, 2026, 4:48 PM EDT
Source: Reuters
Importance Score:
9
NVST
May 06, 2026, 4:18 PM EDT
Filing Type: 10-Q
Importance Score:
8
NVST
Apr 07, 2026, 4:17 PM EDT
Filing Type: DEF 14A
Importance Score:
8
NVST
Feb 12, 2026, 4:18 PM EST
Filing Type: 10-K
Importance Score:
8
NVST
Feb 05, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8